New drug calms dementia agitation in phase 3 trial

NCT ID NCT05271552

Completed Symptom relief Sponsor: BioXcel Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tested a medicine called BXCL501 for calming sudden episodes of agitation in people with dementia. It involved 151 participants who took the medicine only when needed over 12 weeks. The goal was to see if it safely reduces severe restlessness, tension, or aggression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGITATION DEMENTIA

Contacts and locations

Locations

BioXcel Clinical Research Site

Phoenix, Arizona, 85016, United States
BioXcel Clinical Research Site

Long Beach, California, 90806, United States
BioXcel Clinical Research Site

Daytona Beach, Florida, 32117, United States
BioXcel Clinical Research Site

Lady Lake, Florida, 32159, United States
BioXcel Clinical Research Site

Maitland, Florida, 32751, United States
BioXcel Clinical Research Site

Miami Lakes, Florida, 33016, United States
BioXcel Clinical Research Site

North Miami, Florida, 33161, United States
BioXcel Clinical Research Site

Marrero, Louisiana, 70072, United States
BioXcel Clinical Research Site

Springfield, Massachusetts, 01103, United States
BioXcel Clinical Research Site

Berlin, New Jersey, 08009, United States
BioXcel Clinical Research Site

Toms River, New Jersey, 08755, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.